Cardiff Oncology (CRDF) Research & Development (2011 - 2026)

Cardiff Oncology has reported Research & Development for 15 years, with the latest figure at $5.1 million in Q4 2025.

• Quarterly Research & Development fell 47.75% year-over-year to $5.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.3 million (down 4.14% YoY) and the FY2025 annual result came in at $35.3 million, down 4.13% from the prior year.
• Research & Development slipped to $5.1 million in Q4 2025 per CRDF's latest filing, from $8.2 million in the prior quarter.
• Over five years, Research & Development peaked at $11.6 million in Q2 2025 and troughed at $3.3 million in Q1 2021.
• A 5-year average of $7.5 million and a median of $7.9 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 119.82% in 2022, then slumped 47.75% in 2025.
• Over 5 years, Research & Development stood at $5.8 million in 2021, then grew by 10.61% to $6.4 million in 2022, then climbed by 20.51% to $7.8 million in 2023, then grew by 25.11% to $9.7 million in 2024, then plunged by 47.75% to $5.1 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $5.1 million, $8.2 million, and $11.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.